Eli Lilly (LLY -0.5%) is halting the development of its mGlu2/3 schizophrenia drug after a...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY -0.5%) is halting the development of its mGlu2/3 schizophrenia drug after a recent analysis indicated that the treatment was unlikely to succeed in a second Phase III trial, having already failed in a previous study. Another mid-stage trial, which was testing Glu2/3 as an adjunctive treatment with atypical antipsychotics, was unable to meet the main study goal. (PR)